A Phase 1, Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Brincidofovir Administered Intravenously in Healthy Adult Subjects
Phase 1
- Conditions
- adenoviruscytomegalovirussmallpox
- Registration Number
- ACTRN12617000928314
- Lead Sponsor
- Chimerix, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method